⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207971 | 0.86 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL2517327 | 0.77 | — | — | |
| SCHEMBL26672286 | 0.76 | — | — | |
| SCHEMBL11909276 | 0.74 | — | — | |
| SCHEMBL21540334 | 0.74 | COMT (0.33) | — | |
| SCHEMBL31192874 | 0.72 | PIK3CD (0.31) | — | |
| SCHEMBL25791588 | 0.72 | — | — | |
| SCHEMBL31193030 | 0.72 | MEN1 (0.30) | — | |
| SCHEMBL15730720 | 0.71 | GAA (0.37) | — | |
| SCHEMBL20437880 | 0.71 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658662-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
| CN-118852154-A | Carboxamide substituted hetero tricyclic derivative, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024177360-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2024-08-29 | — | — | WO | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-3052485-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| WO-2016054491-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054491-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2015143012-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015051244-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |